NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Allarity Therapeutics, Inc. (ALLR) Stock Analysis

Allarity Therapeutics, Inc. (ALLR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ALLR

$0.88

+$0.00 (+0.43%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ALLR with… →

ALLR Key Statistics

As of Oct 21, 2026
Trading
Open
$0.87
Previous Close
$0.88
Day's Range
0.84–0.90
52-Week Range
0.77–1.84
Volume
88.64K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.57
Valuation
Market Cap
$14.00M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
40.57
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.79
Financials (FY)
Revenue (FY)
$320.00K
Net Income (FY)
−$11.23M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
15.91M
1-Year Return
−40.57%
Dividend and dates
Avg Volume
103.01K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ALLR closed at $0.88, −40.57% over 1 year.

Allarity Therapeutics, Inc. (ALLR) has a market capitalization of $14.00M.

In fiscal 2025, ALLR reported revenue of $320.00K.

ALLR Stock Return by Calendar Year

Allarity Therapeutics, Inc. (ALLR) return since Dec 2021: what $10,000 became

1 year
$10,000 $5,943
−40.57%
3 years
$10,000 $23
−99.77%
Since Dec 2021
$10,000 $0.001
−99.99999%

If you had invested $10,000 in Allarity Therapeutics, Inc. (ALLR) at the close on December 21, 2021, the earliest close on record here, it would have been worth $0.001 at the close on October 21, 2026: −99.99999% in total, −96.44% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−18.56%
2025−7.69%
2024−99.65%
2023−99.87%
2022−97.17%
2021 (partial year)−1.19%

As of October 21, 2026.

ALLR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$320.00K−$11.23M−3,509.7%
2024$0.00−$24.52M—
2023$0.00−$11.90M—
2022$0.00−$16.06M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$320.00K—−$12.61M−$11.23M−3,509.7%
2024$0.00—−$17.54M−$24.52M—
2023$0.00—−$17.13M−$11.90M—
2022$0.00—−$16.89M−$16.06M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ALLR Valuation vs Biotechnology Median

Median of 608 stocks
MetricALLRBiotechnology medianvs median
P/S ratio40.5713.303.1x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Allarity Therapeutics, Inc. (ALLR) at $14.00M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 7.

The most recent close on file for ALLR is $0.88, dated October 21, 2026. That is $0.00 (+0.43%) against the previous close. The 52-week range on file runs from $0.77 to $1.84. The latest close sits 14.38% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $320.00K. The same year closed with a net loss of $11.23M. Trailing earnings per share are −0.79.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $320.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 40.57. On price-to-sales that is 3.1 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −40.57%. Measured over 3 years, that is −86.89% a year compounded. Beta against the wider market is reported at 0.57. Daily returns over the trailing 4 years annualize to a volatility of 117.4%.

Growth & Income

The record shows no dividend for ALLR.

2026 is still running; the total return is −18.56% year to date. The strongest complete calendar year on file is 2025 at −7.69%; the weakest is 2023 at −99.87%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Allarity Therapeutics, Inc. (ALLR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Allarity Therapeutics, Inc. ALLR $14.00M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Allarity Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.

Visit website →